Literature DB >> 12467221

The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

Roberto R Rosato1, Jorge A Almenara, Leanne Cartee, Vicki Betts, Srikumar P Chellappan, Steven Grant.   

Abstract

Interactions between the cyclin-dependent kinase inhibitor flavopiridol (FP) and the histone deacetylase inhibitor sodium butyrate (SB) have been examined in human leukemia cells (U937) in relation to differentiation and apoptosis. Whereas 1 mM of SB or 100 nM of FP minimally induced apoptosis (4% and 10%, respectively) at 24 h, simultaneous exposure of U937 cells to these agents dramatically increased cell death (e.g., approximately 60%), reflected by both morphological and Annexin/propidium iodide-staining features, procaspase 3 activation, and poly(ADP-ribose) polymerase cleavage. Similar interactions were observed in human promyelocytic (HL-60), B-lymphoblastic (Raji), and T-lymphoblastic (Jurkat) leukemia cells. Coadministration of FP opposed SB-mediated accumulation of cells in G0G1 and differentiation, reflected by reduced CD11b expression, but instead dramatically increased procaspase-3, procaspase-8, Bid, and poly(ADP-ribose) polymerase cleavage, as well as mitochondrial damage (e.g., loss of mitochondrial membrane potential and cytochrome c release). FP also blocked SB-related p21WAF1-CIP1 induction through a caspase-independent mechanism and triggered the caspase-mediated cleavage of p27KIP1 and retinoblastoma protein. The latter event was accompanied by a marked reduction in retinoblastoma protein/E2F1 complex formation. However, FP did not modify the extent of SB-associated acetylation of histones H3 and H4. Treatment of cells with FP/SB also resulted in the caspase-mediated cleavage of Bcl-2 and caspase-independent down-regulation of Mcl-1. Levels of cyclins A, D1, and E, and X-linked inhibitor of apoptosis also declined in SB/FP-treated cells. Finally, FP/SB coexposure potently induced apoptosis in two primary acute myelogenous leukemia samples. Together, these findings demonstrate that FP, when combined with SB, induces multiple perturbations in cell cycle and apoptosis regulatory proteins, which oppose leukemic cell differentiation but instead promote mitochondrial damage and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467221

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  14 in total

1.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

2.  Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.

Authors:  Tamer E Fandy; Sharmila Shankar; Douglas D Ross; Edward Sausville; Rakesh K Srivastava
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

3.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 4.  Update on rational targeted therapy in AML.

Authors:  Danielle Shafer; Steven Grant
Journal:  Blood Rev       Date:  2016-02-22       Impact factor: 8.250

Review 5.  Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.

Authors:  Yun Dai; Steven Grant
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

6.  Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Authors:  Alae Yaseen; Shuang Chen; Stefanie Hock; Roberto Rosato; Paul Dent; Yun Dai; Steven Grant
Journal:  Mol Pharmacol       Date:  2012-08-24       Impact factor: 4.436

7.  Epigenetic modifiers: basic understanding and clinical development.

Authors:  Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

8.  Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

Authors:  Syed-Rehan A Hussain; David M Lucas; Amy J Johnson; Thomas S Lin; Alan P Bakaletz; Vinh X Dang; Serge Viatchenko-Karpinski; Amy S Ruppert; John C Byrd; Periannan Kuppusamy; Elliott D Crouser; Michael R Grever
Journal:  Blood       Date:  2008-01-11       Impact factor: 22.113

9.  Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.

Authors:  Stephanie R Pulliam; Samuel T Pellom; Anil Shanker; Samuel E Adunyah
Journal:  Cytokine       Date:  2016-05-30       Impact factor: 3.861

Review 10.  Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

Authors:  Prithviraj Bose; Gary L Simmons; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2013-05-06       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.